ATXS - NASDAQ

Astria Therapeutics, Inc.

ATXS·NASDAQ

$12.58

+0.0000%

HealthcareBiotechnology

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$718.13M

EPS-1.6800

P/E Ratio-7.49

Earnings Date03/10/2026

342.36M

Assets

34%

3Y+168.0%

5Y+719.0%

10Y+433.0%

23.10M

Total Liabilities

100%

3Y+344.0%

5Y+281.0%

10Y+68.0%

319.26M

Total Equity

31%

3Y+161.0%

5Y+794.0%

10Y+532.0%

Astria Therapeutics, Inc. Funding & Solvency Profile

ATXS · NASDAQ

Current Assets

Cash & Cash Equivalents59.82M

Net Receivables0.00

Inventory0.00

Other Current Assets6.51M

Total Current Assets335 M

Non-Current Assets

Property, Plant & Equipment5.11M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets2.61M

Total Non-Current Assets8 M

Total Assets

342.36M

Financial Health Analysis

Current Ratio

17.49x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.07x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

316 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

98% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Astria Therapeutics, Inc. Balance Sheet

ATXS • NASDAQ

Astria Therapeutics, Inc. Balance Sheet	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	59.8M	175.5M	20.5M	86.5M	24.9M	9.9M	15.3M	16.4M	23.6M	62.8M	14.7M	30.5M	5.4K
Short-Term Investments	268.3M	71M	205.9M	39M	20M	26.3M	22.3M	0.0	14.9M	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	328.1M	246.5M	226.4M	125.5M	44.9M	36.2M	37.6M	16.4M	38.5M	62.8M	14.7M	30.5M	5.4K
Prepaids	0.0	0.0	0.0	1.6M	1.4M	2.7M	1.3M	1.1M	1M	772K	354K	107K	0.0
Other Current Assets	6.5M	4.4M	1.3M	0.0	0.0	0.0	0.0	1.1M	1M	0.0	0.0	0.0	181.0
Total Current Assets	334.6M	250.9M	227.7M	127.1M	46.3M	39M	38.9M	17.5M	39.5M	63.6M	15M	30.6M	5.6K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	5.1M	363K	948K	394K	966K	2.3M	56K	321K	568K	504K	288K	308K	585.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	113K	113K	113K	0.0	0.0	0.0
Other Non-Current Assets	2.6M	3.4M	2M	45K	165K	473K	198K	0.0	0.0	22K	654K	113K	-585.0
Total Non-Current Assets	7.7M	3.7M	2.9M	439K	1.1M	2.8M	254K	434K	681K	639K	942K	421K	585.0
Other Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	113.0
Total Assets	342.4M	254.7M	230.6M	127.5M	47.5M	41.8M	39.2M	17.9M	40.2M	64.2M	16M	31M	6.3K
LIABILITIES
CURRENT LIABILITIES
Total Payables	4.3M	1.5M	788K	1.6M	1.5M	1.2M	1.4M	773K	1.4M	1.3M	1.1M	651K	0.0
Accounts Payable	4.3M	1.5M	788K	1.6M	1.5M	1.2M	1.4M	773K	1.4M	1.3M	1.1M	651K	0.0
Accrued Expenses	13.4M	5.7M	4.3M	1.3M	2.1M	1.2M	1.2M	2.4M	3.7M	3.3M	2.8M	2.3M	0.0
Short Term Debt	0.0	0.0	0.0	0.0	0.0	1.2M	0.0	2.5M	3.2M	3.2M	309K	0.0	0.0
Capital Lease Obligations (Current)	1.4M	329K	582K	365K	649K	1.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	40K	168K	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4M	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	0.0	4M	3.4M	2M	2.1M	140K	1.5M	332K	0.0	0.0	0.0	0.0	1.1K
Total Current Liabilities	19.1M	11.6M	9.1M	5.2M	6.4M	5M	4.2M	6M	8.3M	7.8M	4.2M	2.9M	1.9K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5M	5.7M	4.4M	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	56K	89K	319K	177K	80.3M	80.3M	0.0
Total Non-Current Liabilities	4M	0.0	357K	0.0	397K	1M	56K	89K	2.8M	5.9M	84.8M	80.3M	0.0
Capital Lease Obligations	5.4M	329K	939K	365K	1M	2.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	23.1M	11.6M	9.4M	5.2M	6.8M	6.1M	4.2M	6.1M	11.1M	13.7M	89M	83.2M	2K
SHAREHOLDERS' EQUITY
Preferred Stock	95.3M	95.3M	96.4M	96.4M	0.0	0.0	0.0	0.0	0.0	64.2M	80.3M	80.1M	38.7K
Common Stock	57K	41K	28K	13K	4K	12K	7K	24K	19K	15K	1K	0.0	5.0
Additional Paid-In Capital	898.5M	728.3M	632.5M	481.7M	301.6M	259.3M	232.2M	183.2M	173.1M	158.5M	2.3M	1.3M	0.0
Retained Earnings	-674.8M	-580.5M	-507.6M	-455.8M	-260.9M	-223.6M	-197.3M	-171.4M	-144.1M	-108M	-75.4M	-53.5M	-35.4K
Accumulated Other Comprehensive Income/Loss	163K	0.0	-79K	0.0	0.0	0.0	-4K	0.0	-4K	-64.2M	-80.3M	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-80.1M	937.0
Total Stockholders' Equity	319.3M	243.1M	221.2M	122.3M	40.7M	35.7M	34.9M	11.8M	29.1M	50.5M	-73.1M	-52.2M	4.3K
Total Equity	319.3M	243.1M	221.2M	122.3M	40.7M	35.7M	34.9M	11.8M	29.1M	50.5M	-73.1M	-52.2M	4.3K
SUMMARY
Total Liabilities & Equity	342.4M	254.7M	230.6M	127.5M	47.5M	41.8M	39.2M	17.9M	40.2M	64.2M	16M	31M	6.3K
Total Investments	268.3M	71M	205.9M	39M	20M	26.3M	22.3M	113K	14.9M	113K	0.0	0.0	0.0
Total Debt	5.4M	329K	939K	365K	1M	2.3M	0.0	2.5M	5.7M	8.9M	4.7M	0.0	0.0
Net Debt	-54.5M	-175.2M	-19.6M	-86.1M	-23.9M	-7.6M	-15.3M	-13.9M	-17.9M	-53.8M	-9.9M	-30.5M	-5.4K
Shares Outstanding	56,434,894	56,434,894	56,434,894	56,434,894	56,434,894	56,434,894	56,434,894	56,434,894	56,434,894	56,434,894	56,434,894	56,434,894	56,434,894

SEC Filings

ATXS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	January 23, 2026	January 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 21, 2026	January 21, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 23, 2025	December 17, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 12, 2025	November 12, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 14, 2025	October 14, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 12, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 06, 2025	August 06, 2025	2025	View Filing
8-K 8-K 2025 N/A	June 12, 2025	June 11, 2025	2025	View Filing
10-Q 10-Q 2025 Q1 Q1	May 13, 2025	March 31, 2025	2025	View Filing

Showing 1 to 10 of 156 filings

Related Guides

Blog Categories

Continue your ATXS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.